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Abstract 
Predicting the outcome of immunotherapy is essential for efficient treatment. The recent clinical success of 
immunotherapy is increasingly changing the paradigm of cancer treatment. Accordingly, the development of 
immune-based agents is accelerating and the number of agents in the global immuno-oncology pipeline has grown 
60-70% over the past year. However, despite remarkable clinical efficacy in some patients, only few achieve a lasting 
clinical response. Treatment failure can be attributed to poorly immunogenic tumors that do not attract tumor 
infiltrating lymphocytes (TILs). Therefore, we developed positron emission tomography (PET) radiotracers for 
non-invasive detection of CD4+ and CD8a+ TILs in syngeneic mouse tumor models for preclinical studies.  
Methods: Seven syngeneic mouse tumor models (B16F10, P815, CT26, MC38, Renca, 4T1, Sa1N) were quantified 
for CD4+ and CD8a+ TILs using flow cytometry and immunohistochemistry (IHC), as well as for tumor growth 
response to Sym021, a humanized PD-1 antibody cross-reactive with mouse PD-1. Radiotracers were generated from 
F(ab)’2 fragments of rat-anti-mouse CD4 and CD8a antibodies conjugated to the p-SCN-Bn-Desferrioxamine 
(SCN-Bn-DFO) chelator and radiolabeled with Zirconium-89 (89Zr-DFO-CD4/89Zr-DFO-CD8a). Tracers were 
optimized for in vivo PET/CT imaging in CT26 tumor-bearing mice and specificity was evaluated by depletion studies 
and isotype control imaging. 89Zr-DFO-CD4 and 89Zr-DFO-CD8a PET/CT imaging was conducted in the panel of 
syngeneic mouse models prior to immunotherapy with Sym021. 
Results: Syngeneic tumor models were characterized as “hot” or “cold” according to number of TILs determined by 
flow cytometry and IHC. 89Zr-DFO-CD4 and 89Zr-DFO-CD8a were successfully generated with a radiochemical 
purity >99% and immunoreactivity >85%. The optimal imaging time-point was 24 hours post-injection of ~1 MBq 
tracer with 30 µg non-labeled co-dose. Reduced tumor and spleen uptake of 89Zr-DFO-CD8a was observed in CD8a+ 
depleted mice and the uptake was comparable with that of isotype control (89Zr-DFO-IgG2b) confirming specificity. 
PET imaging in syngeneic tumor models revealed a varying maximum tumor-to-heart ratio of 89Zr-DFO-CD4 and 
89Zr-DFO-CD8a across tumor types and in-between subjects that correlated with individual response to Sym021 at 
day 10 relative to start of therapy (p=0.0002 and p=0.0354, respectively). The maximum 89Zr-DFO-CD4 
tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was 
improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018). 
Conclusion: We developed 89Zr-DFO-CD4 and 89Zr-DFO-CD8a PET radiotracers for specific detection and 
whole-body assessment of CD4+ and CD8a+ status. These radiotracers can be used to phenotype preclinical syngeneic 
mouse tumor models and to predict response to an immune checkpoint inhibitor. We foresee development of such 
non-invasive in vivo biomarkers for prediction and evaluation of clinical efficacy of immunotherapeutic agents, such as 
Sym021. 
Key words: Molecular imaging, positron emission tomography (PET), immune cell imaging, immunotherapy, 
immune checkpoint inhibition, PD-1, lymphocytes, tumor infiltrating lymphocytes, T-cells, CD4, CD8. 
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Introduction 
The rapidly evolving field of cancer 
immunotherapy and the clinical success of immune 
checkpoint inhibitors have boosted the development 
of immune-based agents and changed the standard of 
care for many types of cancer [1,2]. Despite 
remarkable clinical efficacy in some patients, others 
fail to develop a durable clinical response. The fact 
that only a subpopulation of patients benefits from 
immune checkpoint inhibitors [3] highlights the 
complexity of the immuno-oncology landscape and 
the strong urgency to develop improved methods to 
predict and monitor therapeutic responses of such 
agents. 
The level of immune infiltration, i.e. immune 
status, in tumors can strongly influence patient 
outcomes for immune checkpoint inhibitors. 
Treatment failure can be attributed to the poorly 
immunogenic, so-called “cold” tumors that do not 
attract tumor infiltrating lymphocytes (TILs). In 
particular, preclinical and clinical research has 
focused on targeting tumors by enhancing cytotoxic 
CD8+ effector function. Indeed, the major players 
exerting tumor-directed killing are thought to be the 
CD8+ T cells which can be either resident or attracted 
to the inflamed tumor microenvironment upon 
presentation of tumor-antigen on MHC class I 
molecules [4,5]. Since most tumors do not express 
MHC class II molecules, the role of CD4+ T cells have 
been indecipherable. However, several characteristics 
of CD4+ T cells place them as required players for 
efficacious anti-tumor immunity. CD4+ T cells 
orchestrate a broad range of immune responses 
including initiating, maintaining and integrating 
adaptive and innate effector functions. Further, 
studies in mice have shown that CD4+ T cells are 
required for inducing CD8+ anti-tumor responses 
[6,7]. Lastly, CD4+ T cells can target tumor cells 
indirectly by modulating the tumor 
microenvironment or directly by cytolytic 
mechanisms [7–10]. Not surprisingly, increasing 
evidence suggests that the presence, location and 
density of both CD4+ and CD8+ lymphocytes in the 
tumor microenvironment of patients are primary 
drivers for productive anti-tumor immune responses 
and are predictors of overall survival [11–16].  
Despite the association of TIL location and 
density in the tumor microenvironment with 
prognosis in various cancers, validated and 
standardized companion diagnostics assays are still 
lacking. Common approaches to detect and monitor 
immune responses are limited to peripheral blood 
lymphocyte analysis and tumor biopsies that are 
invasive, prone to sampling error and may not reflect 
the spatio-temporal dynamics of TILs within the 
tumor. In contrast, non-invasive molecular imaging 
with positron emission tomography (PET) allows for a 
much more comprehensive look at the entire tumor 
and prospective metastases in vivo over time. The 
ability to monitor TILs over the course of therapy with 
PET may allow for early determination of treatment 
efficacy and has thus fueled the development of T cell 
specific PET probes targeting a variety of surface 
markers such as PD-1 [17–19], CTLA-4 [20], CD3+ 
[21,22], CD4+ [23] and CD8+ [24,25] for the purpose of 
detection and monitoring of responses to 
immunotherapy. One key question is however, 
whether these probes can predict the outcome of 
checkpoint blockade therapy. To our knowledge, no 
studies have investigated the predictive value of T cell 
specific imaging and immune phenotyping prior to 
immunotherapy. Thus, we sought to develop specific 
PET radiotracers for non-invasive in vivo detection 
and quantification of TILs in a panel of commonly 
used preclinical syngeneic mouse models mimicking 
a broad patient population prior to immune 
checkpoint inhibition.  
In the present study, we utilize the high 
specificity of antibodies and produce F(ab)’2 
fragments towards CD4 and CD8a surface markers. 
We radiolabel the F(ab)’2 fragments with 
Zirconium-89 (89Zr, t1/2=78.4 hours), an isotope 
well-matched to the biological half-life of F(ab)’2 
fragments and validate the specificity of these 
antibody-based radiotracers for immune phenotyping 
of tumors. Furthermore, we demonstrate that tumor 
uptake of CD4+ and CD8a+ specific tracers is overall 
associated with the tumor growth response to 
Sym021. Sym021 is a recombinant, fully human, 
IgG1-LALA antibody derived from chicken that binds 
human PD-1 with nanomolar affinity and cross-reacts 
with mouse PD-1 with a stability similar to fully 
human antibodies in clinical development [26]. Lastly, 
we show that 89Zr-DFO-CD4 can be used to stratify 
mice into responders and non-responders. 
Materials and methods 
Cell culture and animal models 
Murine cancer cell lines (B16F10 (skin, 
CRL-6475), P815 (mast cell, TIB-64), CT26 (colon, 
CRL-2638), Renca (kidney, CRL-2947), and 4T1 
(breast, CRL-2539)) were purchased from the 
American Type Culture Collection. Murine cancer cell 
lines (Sa1N (fibroblast) and MC38 (colon)) were a 
kind gift from Holbrook Kohrt, Stanford University. 
The CT26, MC38, 4T1, Renca and Sa1N cells were 
cultured in RPMI-1640+Glutamax, 10% fetal bovine 
serum (FBS), 1% penicillin-streptomycin (PS), and the 
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Renca cell line was supplemented with 10 mM 
HEPES, 2 mM sodium pyruvate and 0.1 mM NEAA. 
The B16F10 and P815 cells were cultured in 
DMEM+Glutamax, 10% FBS, 1% PS. P815 was 
supplemented with 1 mM sodium pyruvate. 
All cell lines were maintained at 37°C in a 
humidified incubator containing 5% CO2. Cells were 
harvested in their exponential growth phase and 
resuspended in complete growth media at a 
concentration of 10x106 cells/mL. Cells (100 µL, 1x106 
cells) were subcutaneously injected into the right 
flanks above the hindlimbs in 7-8 week old female 
mice: C57BL/6 (MC38 and B16F10), BALB/c (CT26, 
Renca, and 4T1), A/J (Sa1N), and DBA/2 (P815). 
C57BL/6 and BALB/c mice were supplied by Janvier 
Labs (France), A/J mice by Envigo (Germany) and 
DBA/2 mice by Charles River (Germany) and were 
acclimatized for 1 week prior to experimentation.  
Tumor volume was measured by caliper by 
using the formula (width2×length)×0.52. All animal 
procedures were conducted under a protocol 
approved by the Danish National Animal 
Experiments Inspectorate. 
Flow cytometry 
Tumors were harvested at an average size of 
150-200 mm3 and processed into single cell 
suspensions using a tumor cell isolation kit and the 
GentleMACS Octo Dissociator (Miltenyi Biotec) 
according to the manufacturer’s descriptions. One 
million cells were pre-incubated with Fc block 
(#553141, BD Pharmingen) washed and stained for 
cell surface markers according to standard 
procedures. The following mouse antibodies were 
used: anti-CD8a (PerCP Cy5.5, clone 53-7.6, #100734, 
BioLegend) and anti-CD4 (FITC, clone RM4-5, 
#553046, from BD Pharmingen). Cells were acquired 
on a FACSVerse flow cytometer (BD Biosciences). 
Data were collected using BD FACSuite Software 
(v1.6) and further analyzed with FlowJo v10.4.2 (Tree 
Star Inc.).  
Immunohistochemistry and hematoxylin & 
eosin staining 
Tumors were harvested at an average tumor size 
of 150-200 mm3 and snap frozen. Tissues were 
cryosectioned at 8 µm and immunohistochemical 
(IHC) experiments were conducted as follows: slides 
were fixed in cold acetone or 4% formalin, blocked in 
5% normal mouse serum (Jackson Immunoresearch) 
and incubated with primary antibodies for 1.5 h at 
room temperature. Primary antibodies were anti-CD3 
(Dako, A0452, #280), anti-CD4 (Affymetrix, #14-0042) 
and anti-CD8a (Affymetrix, #14-0081). Sections were 
dried and stained with haematoxylin/eosin in a Leica 
ST4040 automatic stainer. 
Assessment of T cell infiltration was performed 
in a blinded fashion and scored as 0 (negative), 1 
(<150 cells per mm2), 1-2 (150-300 cells per mm2), 2 
(300-500 cells per mm2, 2-3 (500-800 cells per mm2), 
and 3 (>800 cells per mm2). N=3 per syngeneic tumor 
model. 
Generation of F(ab)’2 fragments, conjugation 
and radiolabelling 
F(ab)’2 fragments were generated from 
rat-anti-mouse CD4 clone CK 1.5 (#BE0003-1, 
BioXcell), rat-anti-mouse CD8a clone YTS169.4 
(#BE0117, BioXcell) and rat-anti-mouse IgG2b clone 
LTF-2 (#BE0090, BioXcell) using FabRICATOR 
(#A0-FR1-050, Genovis, Sweden). 2.5 mg of antibody 
in PBS was incubated with 500 units FabRICATOR for 
2.5 hours at 37 °C under continuous rotation. The 
antibody-enzyme mixture was purified by 
preparative HPLC (Yarra-2000 SEC column, 0.1 M 
phosphate buffer, 1 mL/min), yielding isolated 
F(ab)’2 and Fc fragments. F(ab)’2 fragments were 
randomly conjugated to p-SCN-Bn-Desferrioxamine 
(SCN-Bn-DFO, Macrocyclics) by incubating ~ 700 µg 
purified F(ab)’2 fragments with 10x molar excess 
SCN-Bn-DFO dissolved in DMSO in 0.1 M NaHCO3 
(1 hour, 37 °C, pH=9.0). The reaction mixture was 
purified on PD-10 desalting columns (GE Healthcare, 
USA) into PBS resulting in DFO-CD8a, DFO-CD4 and 
DFO-IgG2 precursor.  
89Zr-oxalate (PerkinElmer, the Netherlands) was 
neutralized to pH ~7 with 1 M Na2CO3. Conjugated 
F(ab)’2 fragments (100 µg DFO-CD8a, DFO-CD4, and 
DFO-IgG2 precursor) were incubated with 150 MBq 
neutralized 89Zr-oxalate (1 hour, 37ºC, pH=7.0) 
followed by PD-10 purification into PBS. The 
radiochemical purity at end-of-synthesis was 
determined by radio-thin-layer chromatography 
(radio-TLC) using an eluent of 50 mM EDTA (pH 5.5) 
on silica gel 60 TLC plates, where the antibody 
construct remains at the baseline, while 89Zr4+ ions 
and [89Zr]-EDTA elute with the solvent front. All 
optimization experiments including optimization of 
dose, imaging time-point and in vivo depletion were 
conducted with 89Zr-DFO-CD8a. 
SDS-page 
Full length antibody, purified F(ab)’2 and 
purified Fc fragments were diluted in NuPAGE LDS 
sample buffer (#NP0007, Invitrogen), heated at 70 °C 
for 10 min and loaded onto BoltTM 4-12% Bis-Tris gels 
(#NW04120BOX, Invitrogen). Electrophoresis was 
run on the Mini Gel Tank system (Life Technologies) 
at 200V constant voltage in NuPAGE MES SDS 
running buffer (#NP0002, Invitrogen). Gels were fixed 
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and stained with Coomassie brilliant blue R-250 
(#1610436, Bio-Rad). 
Mouse T cell isolation and immuno-reactivity 
Murine CD4+ and CD8a+ cells were isolated from 
mouse spleen using the magnetic activating cell 
sorting (MACS) technique (CD4+ T cell isolation kit, 
#130-104-454; CD8a+ T cell isolation kit, #130-104-075, 
Miltenyi Biotec). Female BALB/c mice (7-8 weeks old) 
were sacrificed by cervical dislocation and the spleens 
removed aseptically. Spleens were mashed with a 
plunger through a moisturized 70 µm nylon mesh and 
rinsed in FACS buffer (1% BSA, 0.5 mM EDTA in PBS) 
until complete dissociation. Cells were pelleted and 
resuspended in red blood cell lysis buffer 
(#11814389001, Sigma Aldrich), washed in FACS 
buffer and incubated with biotin-antibody cocktail (4 
°C, 5 min) followed by incubation with anti-biotin 
microbeads (4°C, 10 min). Magnetic separation was 
performed on a QuadroMACSTM Manual Separator 
with a pre-rinsed LS column (#130-042-401, Miltenyi 
Biotec) based on negative selection methods. 
The immuno-reactivity of anti-CD4 and 
anti-CD8a F(ab)’2 fragments following radiolabeling 
was assessed according to the Lindmo assay [27]. 
Increasing concentrations of CD4+/CD8a+ cells 
(0.25x106 – 4x107 cells/mL) were incubated with 2 nM 
89Zr-DFO-CD4 or 89Zr-DFO-CD8a for 3 hours at 4°C. 
Cells were centrifuged at 500g for 5 minutes and the 
supernatants and pellets counted in a gamma counter 
(Wizard2, PerkinElmer, Massachusetts, USA). 
Cell-associated radioactivity was calculated as the 
ratio of cell-bound radioactivity to the total amount of 
added radioactivity.  
Optimization of dose and imaging time-point 
Titration of dose and longitudinal imaging was 
performed in CT26 tumor-bearing mice (150-200 mm3) 
and was only performed for 89Zr-DFO-CD8a. Mice 
were injected with 89Zr-DFO-CD8a (1.34 ± 0.1 MBq) 
without or with 5, 10, 30 or 100 µg unlabelled 
CD8a-F(ab)’2 intravenously (total volume ~ 200 µL in 
PBS, N=3/group). Small animal PET/CT imaging was 
performed 1, 4, 24 and 72 hours after injection on an 
Inveon Multimodality PET/CT scanner (Siemens, 
Germany). Mice were anesthetized with sevoflurane 
(3-4% in 80% N2, 20% O2) during PET/CT imaging. 
Static PET data were acquired in list mode with an 
acquisition time of 300, 300, 600 and 900 seconds for 
the 1, 4, 24 and 72 time-point, respectively. Images 
were reconstructed using a 3D maximum a posteriori 
algorithm with CT based attenuation correction. 
Image analysis (Inveon Software, Siemens) was 
performed by drawing CT based regions of interest 
(ROIs) over the tumor, whole heart, liver, kidney, 
muscle, inguinal lymph node (ILN), axillary lymph 
node (ALN) and cervical lymph node (CLN). ROIs 
over the spleen were drawn by PET based 
thresholding. The uptake of 89Zr-DFO-CD8a was 
quantified as % injected dose per gram tissue (%ID/g) 
assuming a soft tissue density of 1 g/cm3. Blood was 
withdrawn by cardiac puncture and mice were 
euthanized after the imaging session, organs resected, 
weighted and the radioactivity counted in a gamma 
counter.  
In vivo depletion 
Mice bearing subcutaneous CT26 tumors 
(150-200 mm3) were treated for three consecutive days 
with intraperitoneal injections of either saline, 300 µg 
of CD8a+ depleting antibody clone 2.43, a full length 
rat-anti-mouse IgG2b (#BE0061, BioXcell), or 300 µg 
DFO-CD8a precursor (N=5/group). Single cell 
suspensions of blood, tumors and spleens were 
obtained according to the above-described method 
and stained for viability (#65-0865-18, ThermoFisher 
Scientific), CD45 (BV480 clone 30-F11, #566095), CD3 
(PE, clone 145-2C11, #100308), CD4 (FITC, clone 
RM4-5, #553047) and CD8a (BV711, clone 53-6.7, 
#563046) (N=2/group). All antibodies were 
purchased from BD Biosciences. Analyses were 
conducted on a LSR-Fortessa flow cytometer (BD) and 
data analysed with FlowJo software (v10, TreeStar 
Inc., USA). 
After end of therapy, saline and CD8a+ depleted 
mice (N=3/group) were injected with 89Zr-DFO-CD8a 
(1.97 ± 0.08 MBq) + 30 µg CD8a-F(ab)’2 intravenously. 
A group of naïve immunodeficient nude mice was 
included to determine distribution in antigen- 
negative mice. Mice were subjected to PET/CT 
imaging with 300 seconds static PET acquisition 24 
hours after injection according to the above-described 
protocol. Mice were euthanized after the imaging 
session and underwent conventional ex vivo 
biodistribution analysis as described above. 
Isotype control imaging 
Mice bearing subcutaneous CT26 tumors 
(150-200 mm3, N=3) were intravenously injected with 
89Zr-DFO-IgG2b (2.2 - 2.6 MBq, 3.1 ± 0.1 µg) + 30 µg 
IgG2b-F(ab)’2 and subjected to PET/CT imaging with 
300 seconds static PET acquisition 24 hours after 
injection according to the above-described protocol. 
Mice were euthanized after the imaging session and 
underwent conventional ex vivo biodistribution 
analysis as described above. 
External radiation therapy and 
autoradiography 
Mice carrying CT26 subcutaneous tumors 
(150-200 mm3) were randomized into two groups 
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(N=8/group) and subjected to 2 Gy external radiation 
therapy (XRT) for three consecutive days at a dose 
rate of 1 Gy/min (320 kV, 12.5 mA) using a small 
animal irradiator (XRAD-320, pXi, CT, USA). Mice 
were placed in the radiation chamber in a restrainer 
allowing total fixation of the leg and the body was 
covered by lead shielding so that only the tumor was 
exposed to radiation. On day 3 after the last radiation 
dose, mice were intravenously injected with 
89Zr-DFO-CD8a (1.12 ± 0.11 MBq) + 30 µg 
CD8a-F(ab)’2 and subjected to PET/CT imaging with 
300 seconds static PET acquisition 24 hours after 
injection according to the above-described protocol. 
Image analysis was performed by drawing CT based 
ROIs over the tumor and PET based thresholding over 
the spleen. 
 Following 89Zr-DFO-CD8a PET two mice from 
each group were subjected to perfusion fixation and 
tumors snap frozen in chilled isopentane in OCT 
medium for autoradiographic measurement. Tumors 
were cryosectioned at 10 µm and slides mounted on 
SuperFrost ULTRA PLUS slides. Intratumoral 
distribution of 89Zr-DFO-CD8a was determined by 
exposing tumor sections to phosphor imaging screens 
for approximately 16 hours. Phosphor screens were 
read on an Amersham Typhoon Imager (GE 
Healthcare, IL, USA). A parallel set of mice subjected 
to an identical treatment regimen (N=6/group) were 
euthanized, spleens and tumors isolated and 
processed into single cell suspensions, stained for 
viability (#65-0865-18, ThermoFisher Scientific), CD45 
(BV480 clone 30-F11, #566095) and CD8a (BV711, 
clone 53-6.7, #563046) according to the 
above-described protocol. Data were collected on a 
LSR-Fortessa flow cytometer (BD) and analysed with 
FlowJo software (v10, TreeStar Inc., USA). 
Small animal PET/CT imaging and Sym021 
treatment 
Once animals representing each syngeneic 
mouse model (B16F10, P815, CT26, MC38, Renca, 4T1, 
Sa1N) reached an average tumor volume of 60-80 
mm3 (8-10 days post inoculation) they were 
randomized into 3 treatment groups; 89Zr-DFO-CD4 
(N=5), 89Zr-DFO-CD8a (N=5) and vehicle (N=5). 
89Zr-DFO-CD4 (0.4-1.1 MBq, 2.1 ± 0.1 µg) and 
89Zr-DFO-CD8a (0.3-0.7 MBq, 1.8 ± 0.3 µg) were 
injected intravenously and mice were subjected to 
PET/CT imaging with 300 seconds static PET 
acquisition 24 hours after injection according to the 
above-described protocol. Image analysis was 
performed by drawing CT based ROIs over the 
tumors and whole heart. Immunotherapy with 
Sym021 was initiated immediately after image 
acquisition. Sym021 was dosed intraperitoneally at 10 
mg/kg 3x weekly for a total of 6 doses. Tumor growth 
was monitored 3x weekly for evaluation of 
therapeutic response and the tumor growth inhibition 
(TGI) was calculated relatively to the mean tumor 
volume of the control group to correct for inter-model 
tumor growth differences. TGI was expressed as % 
and calculated as ((average tumor volume(day 
10)control group – tumor volume(day 10)treated mouse)/ 
average tumor volume(day 10)control group) x 100. Mice 
were euthanized at the first tumor measurement 
above 1,500 mm3.  
Statistical analyses 
Data are expressed as mean ± SEM. One-way 
ANOVA with post hoc test corrected for multiple 
comparisons (Tukey) was applied to test the effect of 
depletion and compare tumor volumes between 
treatment groups. Student’s t-test was performed to 
test the effect of external radiation therapy and 
compare tumor-to-heart ratios between responders 
and non-responders. For presentation of mean tumor 
growth over time, carry-forward of tumor volumes 
was performed until the last day where >50% of the 
treatment group was alive to account for missing 
points. Two-way ANOVA with repeated measures 
was applied to compare the tumor volumes over time. 
Linear regression analyses were performed to test for 
correlations and the Log-rank test (Mantel-Cox) was 
applied for survival analyses. P values ≤ 0.05 were 
considered statistically significant. Statistical analyses 
were performed using GraphPad Prism 7.0c 
(GraphPad Software, CA, USA). 
Results 
Generation of radiolabelled F(ab)’2 fragments 
Rat-anti-mouse-CD4, rat-anti-mouse-CD8a and 
rat-anti-mouse-IgG2b were successfully digested in 
the hinge region yielding F(ab)’2 and Fc fragments 
(Figure 1A). SDS-page analysis confirmed the 
digestion efficiency and revealed F(ab)’2 at 100 kDa 
(lane 4, 8) with no presence of Fc or full-length 
antibody in the final product (Figure 1B). F(ab)’2 
fragments were conjugated to the SCN-Bn-DFO 
chelator and radiolabeled with 89Zr with a 
radiochemical yield of 11.9 ± 2.6, 17.5 ± 4.3 and 37 
MBq for 89Zr-DFO-CD4, 89Zr-DFO-CD8a and 89Zr- 
DFO-IgG2b, respectively. All tracers were >99% pure 
as assessed by radio-TLC. Representative HPLC 
chromatograms of digested rat-anti-mouse-CD8a+ 
and 89Zr-DFO-CD8a are shown in Figure 1C-D, where 
a major UV peak for F(ab)’2 corresponding with the 
radioactive peak, and two minor peaks for full-length 
antibody and Fc were observed (Figure 1D). The 
immuno-reactivity of 89Zr-DFO-CD4 and 89Zr-DFO- 
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CD8a towards CD4 and CD8a expressing splenocytes 
was estimated to 90.5 ± 0.6% and 86.7 ± 0.7%, 
respectively. Specifications of each tracer are 
summarized in Table 1. 
 
Table 1: Specifications of tracers 
 89Zr-DFO-CD4 89Zr-DFO-CD8a 89Zr-DFO-IgG2b 
Radiochemical yield 
(MBq) 
11.9 ± 2.6 17.5 ± 4.3 37 
Purity (%) >99 >99 >99 
Specific activity 
(MBq/mg) 
218.7 ± 42.3 200.5 ± 39.5 553.7 
Immunoreactivity (%) 90.5 ± 0.6 86.7 ± 0.7 - 
Activity injected* (MBq) 0.8 ± 0.03  
[0.4-1.1] 
0.5 ± 0.02  
 [0.3-0.7] 
2.4 ± 0.4  
[2.2-2.6] 
Protein dose injected* (µg) 2.1 ± 0.1 1.8 ± 0.3 3.3 ± 0.1 
Values are mean ± SEM. 
*Doses listed for 89Zr-DFO-CD4/CD8a are from the efficacy study. 
 
Optimization of imaging parameters 
Radiolabeled F(ab)’2 fragments were initially 
evaluated in CT26 tumor-bearing mice to optimize 
imaging parameters for tumor visualization. 
89Zr-DFO-CD8a was titrated with cold doses of 
CD8a-F(ab)’2 ranging from 0-100 µg where uptake 
was primarily seen in lymphoid tissue, i.e. spleen and 
lymph nodes. Retention in kidneys was also observed 
as expected for radiolabeled antibody fragments [28]. 
Uptake in lymphoid tissue significantly decreased 
with increasing co-dose as evident from the 
representative PET images (Figure S1) and ex vivo 
biodistribution 72 hours post-injection (Figure 1E). 
Contrary, availability of 89Zr-DFO-CD8a for tumor 
accumulation was evident and uptake increased from 
1.28 ± 0.17 to 2.45 ± 0.28 % injected dose per gram 
(%ID/g) with increasing dose of CD8a-F(ab)’2 (Figure 
1F, Table S1). Importantly, the tumor-to-muscle 
(Figure 1G) and tumor-to-blood (Figure 1H) ratios 
also increased with increasing dose. However, a 
decrease in the tumor-to-muscle ratio of 
89Zr-DFO-CD8a was observed at 100 µg (Table S1). 
Based on these results 30 µg was chosen as the 
optimal co-dose.  
  Temporal in vivo distribution of protein 
dose-optimized 89Zr-DFO-CD8a by longitudinal PET 
imaging at 1, 4, 24 and 72 hours post-injection is 
depicted in Figure 1I. High accumulation was seen in 
kidney, spleen and lymph nodes which increased 
over the imaging time-course. However, no further 
improvement in image contrast was seen beyond 24 
hours (Figure S2). Tumor uptake was 2.88 ± 0.71, 4.55 
± 1.07, 5.0 ± 1.3 and 2.68 ± 0.56 % ID/g for the 1, 4, 24 
and 72 hour time-points, respectively. Despite high 
kidney uptake, 24 hours post-injection was chosen as 
optimal for imaging due to measurable tumor growth 
resulting in dilution of tumor PET signal and limited 
gain in image contrast at 72 hours. 
Specificity of 89Zr-DFO-CD8a PET signal 
To evaluate the specificity of 89Zr-DFO-CD8a 
towards CD8a, CT26 tumor-bearing mice were treated 
with CD8a+ depleting antibody. Furthermore, to 
ensure that 89Zr-DFO-CD8a does not perturb CD8a+ 
populations in vivo, a group of mice received equally 
high doses of DFO-CD8a precursor. Flow cytometric 
analyses showed a >95% reduction in CD45+CD8a+ 
cells in blood and spleens and a ~85% reduction in the 
tumors of mice treated with CD8a+ depleting mAb 
(Figure 2A-B). Importantly, high dose DFO-CD8a 
precursor did not alter CD45+CD8a+ populations in 
any of the analysed tissues. 89Zr-DFO-CD8a PET was 
able to detect the loss of CD45+CD8a+ cells in the 
spleen as visualized by the representative PET/CT 
images (Figure 2C). When injected into 
antigen-negative mice lacking mature T and B 
lymphocytes, 89Zr-DFO-CD8a uptake in spleen was 
similar to that of CD8a+ depleted mice confirming the 
specificity of 89Zr-DFO-CD8a (Figure 2C). Ex vivo 
biodistribution confirmed a significant decrease in 
89Zr-DFO-CD8a uptake in spleen (p<0.05) and lymph 
nodes (p<0.01) of CD8a+ depleted mice (Figure 2D). 
Uptake of 89Zr-labeled isotype control antibody 
(89Zr-DFO-IgG2b) in lymphoid tissue was low (~1-3 
%ID/g) and was similar to the 89Zr-DFO-CD8a uptake 
in CD8a+ depleted mice (p=0.55). To compare the 
accumulation of 89Zr-DFO-CD8a and 89Zr-DFO-IgG2b 
in tumors, the tumor uptake was normalized to the 
blood pool in order to account for an observed 
difference in circulation time between the probes. The 
tumor-to-blood ratio of 89Zr-DFO-CD8a was 
significantly lower in CD8a+ depleted mice compared 
to control mice (5.6 ± 0.03 vs. 8.3 ± 0.32, p=0.011, 
Figure 2E). In addition, the tumor-to-blood ratio of 
89Zr-DFO-IgG2b was 1.9 ± 0.68 and significantly lower 
than that of control (p=0.0001) and CD8a+ depleted 
(p=0.0024) mice.  
 Fractionated XRT was applied to CT26 
tumor-bearing mice to investigate whether 
treatment-induced changes in CD8+ populations [29] 
could be detected with the probes (Figure 2F). XRT 
induced lymphocyte infiltration in tumors and 
spleens of CT26 tumor-bearing mice that was detected 
by 89Zr-DFO-CD8a PET/CT (Figure 2G, Figure S3). 
Mean tumor uptake increased from 3.8 ± 0.2 to 4.9 ± 
0.1 %ID/g (p=0.0006) and mean spleen uptake 
increased from 8.7 ± 0.5 to 11.2 ± 0.5 %ID/g 
(p=0.0022). Ex vivo autoradiographic measurement of 
89Zr-DFO-CD8a visualized this distribution pattern in 
tumors between treated and non-treated groups 
(Figure 2F). Further, flow cytometric analysis 
confirmed the increased numbers of CD45+CD8a+ 
cells in tumors (p=0.0287) and spleens (p=0.0002) of 
irradiated mice (Figure 2H). 
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Characterization of syngeneic mouse tumor 
models  
Immune status of a panel of seven subcutaneous 
syngeneic mouse tumor models was analysed by 
immunohistochemistry and flow cytometry with 
respect to their capacity to attract TILs, i.e. CD4+ and 
CD8a+ cells. Representative immunohistochemical 
images and flow cytometric plots are shown in Figure 
3A, representing a model with low (B16F10) and high 
(Sa1N) numbers of CD4+ and CD8a+ cells. 
 
 
Figure 1: Development and optimization of radiolabeled F(ab)’2 fragments for PET imaging. (A) Schematic illustration of preparation of F(ab)’2 fragments from full 
length antibodies using FaBRICATOR (IdeS protease). (B) SDS-page of non-digested (lane 2+6), crude antibody mixture (lane 3+7) and purified F(ab)’2 (lane 4+8) and Fc 
fragments (lane 5+9) of anti-mouse CD4 and anti-mouse CD8a. (C) Representative HPLC chromatogram of crude anti-mouse CD8a antibody mixture used for preparative 
purification. (D) Representative HPLC chromatogram of 89Zr-DFO-CD8a after PD10 purification at end-of-synthesis. (E) Ex vivo biodistribution 72 hours post-injection of 
89Zr-DFO-CD8a in major organs and (F) CT26 tumors with increasing doses of unlabeled CD8a-F(ab)’2 measured by gamma counting and expressed as %ID/g (N=3/dose). (G) 
Tumor-to-muscle and (H) tumor-to-blood ratio of uptake quantified by gamma counting 72 hours post-injection of 89Zr-DFO-CD8a (N=3/dose). (I) Image-derived 
biodistribution of dose-optimized mean 89Zr-DFO-CD8a uptake in major organs and tumor based on ROI analysis and expressed as mean %ID/g in CT26 tumor-bearing mice 
over the imaging time-course (N=3). Data are presented as mean ± SEM. Ab: antibody; ALN: axillary lymph node; CLN: cervical lymph node; ILN: inguinal lymph node; %ID/g: % 
injected dose per gram tissue. 
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Figure 2: Specificity of 89Zr-DFO-CD8a in depleted, antigen-negative and tumor-bearing mice. (A) Representative dot plots of median fluorescent intensity of 
CD4-FITC (y-axis) and CD8a-BV711 (x-axis) measured by flow cytometric analysis of blood, spleen and tumors of control (N=2), CD8a+ depleted (N=2) and DFO-CD8a treated 
(N=2) CT26 tumor-bearing mice. (B) Depletion with CD8a 2.43 mAb reduced the percentage of CD45+CD8a+ cells in blood, spleen and tumor whereas DFO-CD8a precursor 
did not change CD45+CD8a+ populations (N=2/group). (C) Representative axial PET/CT images 24 hours post-injection of 89Zr-DFO-CD8a in control, CD8a+ depleted and 
NMRI nude (antigen-negative) mice. Arrows designate the spleen. (D) Ex vivo biodistribution of 89Zr-DFO-CD8a and 89Zr-DFO-IgG2b (isotype control) in lymphoid tissue. Mean 
89Zr-DFO-CD8a uptake was significantly reduced in CD8a+ depleted mice (N=3/group). (E) The 89Zr-DFO-CD8a tumor-to-blood ratio was lowered in CD8a+ depleted mice 
compared to control mice (p=0.011) (N=3/group). The 89Zr-DFO-IgG2b (isotype control) tumor-to-blood ratio was significantly different than the 89Zr-DFO-CD8a 
tumor-to-blood ratio in control (p=0.0001) and CD8a+ depleted mice (p=0.0024). (F) Autoradiography of tumors showed increased 89Zr-DFO-CD8a uptake in tumors subjected 
to fractionated external radiation therapy (XRT, 3x2Gy). (G) XRT (3x2Gy) increased the mean 89Zr-DFO-CD8a uptake in tumors (p=0.0006) and spleens (p=0.0022) of CT26 
tumor-bearing mice (N=16/group) that was confirmed by (H) flow cytometric analysis of CD45+CD8a+ cells (N=6/group). Data are presented as mean ± SEM and the significance 
levels are indicated by asterisks (*). *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001, ns=no significance. ALN: axillary lymph node; CLN: cervical lymph node; ILN: inguinal 
lymph node; XRT: external radiation therapy; %ID/g: % injected dose per gram tissue. 
Table 2: Summarized IHC, flow cytometry, PET imaging and efficacy data. 
   89Zr-DFO-CD4  
 
  89Zr-DFO-CD8a     
Model CD4+ IHC 
(score) 
CD4+ flow 
(%) 
Tumor 
(max 
%ID/g) 
Tumor / 
heart ratio 
(max) 
CD8a+ 
IHC 
(score) 
CD8a+ 
flow (%) 
Tumor 
(max %ID/g) 
Tumor / 
heart ratio 
(max) 
Immune 
phenotype 
Mean 
response to 
Sym021 
Responders / 
non-responders 
CD4+ PET (N) 
Responders / 
non-responders 
CD8a+ PET (N) 
B16F10 0.7 ± 0.3 0.30 ± 0.10 10.3 ± 0.7 5.28 ± 0.68 1.0 ± 0.0 0.37 ± 0.19 9.7 ± 0.9 4.6 ± 0.67 Cold No response 0/5 0/5 
P815 2.0 ± 0.3 0.39 ± 0.05 14.9 ± 0.7 6.61 ± 0.96 1.0 ± 0.0 0.39 ± 0.05 17.9 ± 0.4 5.15 ± 0.38 Cold Partial 
response 
2/3 0/5 
CT26 1.3 ± 0.2 1.14 ± 0.31 7.5 ± 0.3 8.15 ± 0.44 1.5 ± 0.0 2.95 ± 0.73 8.9 ± 0.5 9.25 ± 0.98 Hot Responsive 1/4 1/4 
MC38 1.3 ± 0.2 1.48 ± 0.2 7.7 ± 0.4 7.62 ± 0.28 1.3 ± 0.2 1.73 ± 0.42 7.1 ± 0.5 8.25 ± 0.6 Hot Responsive 0/5 0/5 
Renca 1.5 ± 0.0 0.77 ± 0.46 9.5 ± 0.5 9.99 ± 0.3 1.5 ± 0.0 0.29 ± 0.21 11.3 ± 0.8 10.15 ± 1.09 Hot/Cold Responsive 0/5 0/5 
4T1 1.2 ± 0.2 1.49 ± 0.39 11.9 ± 0.7 9.05 ± 0.4 1.3 ± 0.2 0.83 ± 0.23 12.6 ± 0.3 8.11 ± 0.41 Hot Responsive 0/5 0/5 
Sa1N 1.0 ± 0.0 1.82 ± 0.66 15.6 ± 1.4 8.49 ± 0.44 1.8 ± 0.6 1.57 ± 0.41 15.6 ± 0.8 7.26 ± 0.4 Hot Responsive 2/3 2/3 
Values are mean ± SEM. %ID/g: % injected dose per gram tissue. 
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Figure 3: Characterization of syngeneic mouse models by CD4+ and 
CD8a+ subsets. (A) Representative sections from immunohistochemical (IHC) 
staining of CD4+ and CD8a+, and hematoxylin and eosin (HE) staining in a tumor 
model with low (B16F10) and high (Sa1N) intensity staining (left panel). 
Representative dot plots of median fluorescent intensity of CD4-FITC (y-axis) and 
CD8a-PerCP-Cy5.5 (x-axis) of flow cytometric analysis of CD4+ and CD8a+ cells in a 
tumor model with low (B16F10) and high (Sa1N) intensity staining (right panel). (B) 
Agreement between flow cytometric and IHC analysis of CD4+ and (C) CD8a+ 
subsets revealed clustering of tumor types into hot (red) and cold (blue) areas. 
N=6/model for flow cytometry, N=3/model for IHC. HE: hematoxylin and eosin; 
IHC: immunohistochemistry. 
 
Varying degree of lymphocyte infiltration was 
observed and tumor types were stratified into 
immunologically “hot” or “cold” tumors based on 
their numbers of CD4+ and CD8a+ cells [12,30–32]. 
Sa1N, MC38, CT26, and 4T1 presented with the 
highest number of infiltrating CD4+ and CD8a+ T cells 
and were defined as “hot” tumors (Figure 3B-C, read 
area). The lowest numbers of CD4+ and CD8a+ cells 
were found in B16F10 (Figure 3B-C, blue area), 
defined as a “cold” tumor, and intermediate T cell 
numbers were found in Renca and P815, although 
high CD4+ numbers were found in both models based 
on IHC score only. Quantitative analysis of all models 
is illustrated in Figure S4 and summarized in Table 2.  
CD4+ and CD8a+ PET imaging in syngeneic 
mouse models 
Baseline PET imaging of CD4+ and CD8a+ was 
conducted in the same panel of syngeneic mouse 
models prior to treatment with Sym021 to evaluate 
the predictive value of TIL imaging for treatment 
response across various tumor types (Figure 4A). 
Quantitative ROI analysis of 89Zr-DFO-CD4 
maximum tumor uptake is depicted in Figure 4B 
ranked from high to low and revealed uptake levels of 
15.6 ± 1.4 (Sa1N), 14.9 ± 0.65 (P815), 11.9 ± 0.74 (4T1), 
10.2 ± 0.67 (B16F10), 9.5 ± 0.5 (Renca), 7.65 ± 0.35 
(MC38) and 7.53 ± 0.25 (CT26) %ID/g. Likewise, 
89Zr-DFO-CD8a uptake is illustrated in Figure 4C and 
was 17.9 ± 1.4 (P815), 15.6 ± 0.8 (Sa1N), 12.6 ± 0.3 
(4T1), 11.3 ± 0.84 (Renca), 9.6 ± 0.9 (B16F10), 8.9 ± 0.5 
(CT26) and 7.1 ± 0.5 (MC38) %ID/g. Tumor-to-heart 
ratios (tumormax/heartmean) were calculated to correct 
for activity remaining in the blood and were 9.99 ± 0.3 
(Renca), 9.05 ± 0.4 (4T1), 8.49 ± 0.44 (Sa1N), 8.15 ± 0.44 
(CT26), 7.62 ± 0.28 (MC38), 6.61 ± 0.96 (P815) and 5.28 
± 0.68 (B16F10) for 89Zr-DFO-CD4 (Figure 4D). 
Similarly, the 89Zr-DFO-CD8a tumor-to-heart ratios 
are illustrated in Figure 4E and were 10.15 ± 1.09 
(Renca), 9.25 ± 0.98 (CT26), 8.25 ± 0.6 (MC38), 8.11 ± 
0.41 (4T1), 7.26 ± 0.4 (Sa1N), 5.15 ± 0.38 (P815) and 4.6 
± 0.67 (B16F10). Representative maximum intensity 
projection PET images for each model are shown in 
Figure 4F, where 89Zr-DFO-CD4 and 89Zr-DFO-CD8a 
clearly visualized the tumors 24 hours post-injection. 
Representative axial PET/CT images of the tumor and 
heart for each model are shown in Figure S5. Mean 
tumor uptake and tumor-to-heart (tumormean/ 
heartmean) ratios are depicted in Figure S6A-B. 
Overall, the mean and maximum tumor-to-heart 
ratios of 89Zr-DFO-CD4 and 89Zr-DFO-CD8a were in 
agreement with flow cytometric analysis of CD4+ 
(Figure S6C-D, top panel) and CD8a+ (Figure S6C-D, 
bottom panel) numbers across syngeneic mouse 
tumor models.  
Tumor growth response to Sym021 
Following PET imaging, mice were subjected to 
immunotherapy with Sym021. All groups, within 
each model and across models, had equal mean tumor 
volumes at day -1 relative to start of therapy (Figure 
S7). Tumor growth curves for Sym021 treated mice 
(N=10/group) are shown in Figure 5 for each model 
and were compared to corresponding vehicle-treated 
animals (N=5/group) that were not subjected to CD4+ 
or CD8a+ PET imaging. Sym021 effectively inhibited 
tumor growth in CT26 (p=0.0029), MC38 (p=0.0002), 
Renca (p<0.0001), 4T1 (p=0.0011) and Sa1N (p<0.0001) 
at 10 mg/kg. No overall effect of Sym021 was found 
in B16F10 (p=0.49) and P815 (p=0.1721) tumor models. 
Mice were terminated when reaching humane 
endpoints or at study end at day 65, where no signs of 
tumor regrowth was apparent. Due to issues with 
wound formation and/or necrosis in certain models 
humane endpoints were reached prematurely for 
P815 (~500 mm3) and 4T1 (~1000 mm3).  
It is noteworthy, that inter-model efficacy 
seemed to be overall associated with the immune 
status, since models with the highest number of CD4+ 
and CD8a+ cells according to combined IHC, flow 
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cytometry and PET tumor-to-heart ratios (Sa1N, 4T1, 
CT26 and MC38), demonstrated significantly reduced 
tumor growth in response to Sym021 (Figure 3B-C). In 
contrast, models with the lowest numbers of CD4+ 
and CD8a+ cells (B16F10 and P815) exhibited no 
response to Sym021. 
Sym021 efficacy correlates with PET imaging 
of tumor-infiltrating lymphocytes 
To investigate the predictive value of 
89Zr-DFO-CD4 and 89Zr-DFO-CD8a the TGI from day 
0 to day 10 in Sym021 treated mice relative to the 
growth of the control group was compared to the 
maximum baseline tumor-to-heart ratio of 
89Zr-DFO-CD4 and 89Zr-DFO-CD8a. Day 10 was the 
latest day post-therapy initiation with sufficient mice 
in the control group across models. The relative tumor 
growth against PET tumor-to-heart ratio was plotted 
for individual mice across all tumor models (Figure 
6A) as well as for the mean of each tumor model 
 
Figure 4: Experimental design and PET imaging of 89Zr-DFO-CD4 and 89Zr-DFO-CD8a in a panel of syngeneic mouse models. (A) Overview of the timing of 
tumor inoculation, 89Zr-DFO-CD4 and 89Zr-DFO-CD8a injections, PET imaging and therapy dosing. Sym021 (10 mg/kg) was dosed 6 times over two weeks and efficacy 
monitored until humane endpoints were reached. (B) Maximum 89Zr-DFO-CD4 and (C) 89Zr-DFO-CD8a uptake in syngeneic mouse models quantified from PET ROI analysis 
of tumors and expressed as %ID/g 24 hours post-injection of tracer ranked from low (left) to high (right). Tumor-to-heart ratios of the maximum (D) 89Zr-DFO-CD4 and (E) 
89Zr-DFO-CD8a uptake quantified from PET ROI analysis and expressed as %ID/g 24 hours post-injection of tracer ranked from low (left) to high (right). (F) Representative 
coronal maximum intensity projection PET images of 89Zr-DFO-CD4 (top panel) and 89Zr-DFO-CD8a (bottom panel) for each model. The PET acquisition time was 300 
seconds. White circles designate the tumor. Data are presented as mean ± SEM. %ID/g: % injected dose per gram tissue. 
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(Figure 6B). Color coding of the different models 
clearly demonstrated the heterogeneity within each 
model and across models. The maximum 
89Zr-DFO-CD4 (p=0.0002) and 89Zr-DFO-CD8a 
(p=0.0354) tumor-to-heart ratio were found to 
correlate with the relative TGI at day 10 post therapy 
initiation, although the correlation appeared stronger 
for 89Zr-DFO-CD4. There was no association between 
the mean 89Zr-DFO-CD4 (p=0.0817) or 89Zr-DFO-CD8a 
(p=0.0651) tumor-to-heart ratio and the relative TGI at 
day 10 post therapy initiation (Figure S8).  
 
 
Figure 5: Efficacy of immunotherapy with Sym021 in syngeneic mouse models. Therapy with Sym021 (green) at 10 mg/kg over two weeks effectively inhibited tumor 
growth in CT26 (p=0.0029), MC38 (p=0.0002), Renca (p<0.0001), 4T1 (p=0.0011) and Sa1N (p<0.0001) compared to vehicle-treated animals (grey). No effect of Sym021 was 
observed in B16F10 (p=0.49) and P815 (p=0.1721) tumor models. The grey area indicates the treatment period. Mice were euthanized after first tumor measurement above 
1,500 mm2 except in the case of the P815 and 4T1 model, where humane endpoints were reached prematurely. Mean tumor volumes of treatment groups are presented with 
carry-forward of tumor volumes from euthanized mice until the last day where >50% of the group was alive. N=5 for vehicle-treated animals, N=10 for Sym021 treated animals. 
Data are presented as mean ± SEM and the significance levels are indicated by asterisks (*). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
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89Zr-DFO-CD4 predicts treatment outcome 
As evident from the tumor growth curves in 
Figure 5, three of the Sym021 responding tumor 
models showed pronounced effect on tumor growth 
with 1-2 responders in each model that did not 
regrow during the entire study period of 65 days. 
Responders among mice subjected to pre-therapy 
89Zr-DFO-CD4 PET were found in the CT26 (N=1), 
Sa1N (N=2) and P815 (N=2) models. Responders 
among mice subjected to pre-therapy 89Zr-DFO-CD8a 
PET included CT26 (N=1) and Sa1N (N=2). When 
comparing the mean and maximum 89Zr-DFO-CD4 
tumor-to-heart ratios of responders (N=5) and 
non-responders among all mice (N=30), irrespective 
of tumor model, a significantly increased maximum 
89Zr-DFO-CD4 tumor-to-heart ratio was found in the 
responders (p=0.0306) (Figure 6C, top panel). This 
difference was more prominent when comparing the 
intra-model responders (N=5) with non-responders 
(N=10, p=0.0097) (Figure 6D, top panel). No 
difference in the 89Zr-DFO-CD4 mean tumor-to-heart 
ratio was found when comparing responders with 
non-responders among all mice (p=0.8298) or 
intra-model mice (p=0.1529). Further, no difference 
between the maximum 89Zr-DFO-CD8a tumor-to- 
heart ratio in responding mice (N=3) was found when 
comparing to all non-responding mice (N=32, 
p=0.8248) nor intra-model mice (N=12, p=0.9352) 
(Figure 6C-D, bottom panel). 
 All mice in the baseline 89Zr-DFO-CD4 
responding group presented with a maximum 
tumor-to-heart ratio >9 (average 9.79 ± 0.37), whereas 
the non-responding group presented with a 
maximum 89Zr-DFO-CD4 tumor-to-heart ratio of 7.73 
± 0.35. We therefore speculated whether the 
maximum 89Zr-DFO-CD4 tumor-to-heart ratio could 
be used to stratify mice into subgroups that respond 
to Sym021 and predict overall survival. Based on the 
maximum 89Zr-DFO-CD4 tumor-to-heart ratio in the 
Sym021 responding group, 9 was chosen as cut-off 
value in a retrospective analysis. Overall survival was 
improved in mice with a tumor-to-heart ratio >9 of 
89Zr-DFO-CD4 (p=0.0018), with a median survival of 
51 days compared to 23 days in the <9 group (Figure 
6E, top panel). A similar analysis was performed for 
89Zr-DFO-CD8a, where the tumor-to-heart ratio of the 
responding group was 7.32 ± 0.63. Overall survival 
was not improved in mice with a tumor-to-heart ratio 
>7 of 89Zr-DFO-CD8a (p=0.5037), with a median 
survival of 20 days compared to 16 days in the <7 
group (Figure 6E, bottom panel). 
 
 
 
Figure 6: 89Zr-DFO-CD4 PET predicts Sym021 treatment outcome in syngeneic mouse models. (A) The tumor growth inhibition (TGI) from day 0 til day 10 in 
Sym021 treated mice (10 mg/kg) relative to the growth of the control group expressed as % correlated with the maximum tumor-to-heart ratio of 89Zr-DFO-CD4 (p=0.0002, 
top panel) and 89Zr-DFO-CD8a (p=0.0354, bottom panel) in individual mice across all models (N=35/tracer). (B) Average TGI until day 10 relative to start of therapy with 10 
mg/kg Sym021 (day 0) expressed as % for each model plotted against the average maximum tumor-to-heart ratio of 89Zr-DFO-CD4 (top panel) and 89Zr-DFO-CD8a (bottom 
panel) for each model (N=35/tracer, N=5/model). (C) Mean and maximum tumor-to-heart ratio of 89Zr-DFO-CD4 (top panel) and 89Zr-DFO-CD8a (bottom panel) in 
responders (Rs) and non-responders (N-Rs) across all models (N=35/tracer). Responders (N=5) had higher maximum 89Zr-DFO-CD4 tumor-to-heart ratio than all 
non-responders (N=30) (p=0.0306, top panel). (D) Mean and maximum tumor-to-heart ratio of 89Zr-DFO-CD4 (top panel) and 89Zr-DFO-CD8a (bottom panel) in responders 
and non-responders of the models where responders were found. Responders (N=5) had higher maximum 89Zr-DFO-CD4 tumor uptake than the non-responders of the models 
were responders were found (N=10) (p=0.0097, top panel). (E) Stratification of mice across all models based on their maximum tumor-to-heart ratio of 89Zr-DFO-CD4 (top 
panel) and 89Zr-DFO-CD8a (bottom panel) resulted in improved overall survival of mice with a maximum 89Zr-DFO-CD4 tumor-to-heart ratio >9 (N=5) compared to the <9 
group (N=30) (p=0.0018). All tumor and heart uptake values of 89Zr-DFO-CD4 and 89Zr-DFO-CD8a were derived from PET ROI analysis and expressed as %ID/g. Data are 
presented as mean ± SEM and the significance levels are indicated by asterisks (*). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, ns = no significance. N-Rs: 
non-responders; ROI: region of interest; Rs: responders; %ID/g: % injected dose per gram tissue. 
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Discussion 
Immunotherapy has recently emerged as a 
particularly effective strategy for treating several 
types of cancer. Sym021 is a newly developed, 
humanized antibody targeting the PD-L1/PD-1 
interaction between tumor cells and cells of the 
immune system, boosting the reactivity of primarily 
PD-1 expressing T lymphocytes towards tumor cells 
[33]. Alongside the rapid development of immune- 
targeting agents the necessity of developing methods 
for reliably identifying patients that would respond to 
therapy becomes apparent. Companion diagnostic 
methods should preferably be non-invasive and 
sensitive to the dynamic changes in immune 
populations to ease the translation into clinical use. In 
the present study, we developed specific tracers for 
non-invasive PET imaging of CD4+ and CD8a+ cells to 
enable quantification of these lymphocytes on a 
whole-body level in mice. We applied the developed 
PET procedures to seven different syngeneic mouse 
tumor models and demonstrate that 89Zr-DFO-CD4 
can be a predictor of tumor growth response and 
overall survival to Sym021. 
 After successful radiolabeling the tracers 
retained in vitro binding to target with immuno- 
reactivities > 85%. In vivo studies with 89Zr-DFO-CD8a 
showed effective targeting to CD8a+ tissue, i.e. lymph 
nodes and spleen in antigen-positive mice. The 
accumulation of tracer in lymphoid tissue was 
extremely high as expected for antigen-dense tissues. 
This phenomenon, commonly referred to as the 
antigen-sink, typically results in faster clearance at 
low antibody doses [34]. We therefore titrated the 
total protein dose to saturate endogenous target and 
increase the availability of the tracer for tumor 
accumulation. Co-dosing with CD8a-F(ab)’2 increased 
the tumor uptake ~2-3 fold, which is quite substantial 
considering the relatively low target-abundance as 
opposed to tumor surface markers. The co-dosing 
strategy in the development of antibody-based PET 
tracers is increasingly debated. To visualize a target 
that is more abundant in non-tumor tissues is not a 
common approach in the utilization of PET within 
oncology. Therefore, a dose optimization can be 
essential to obtain sufficient imaging signal, however, 
with the risk of also perturbing the binding of tracers 
to intratumoral T cells. Importantly, the 30 µg co-dose 
did not block tumor uptake as illustrated by the 
tumor-to-background ratios in this study. In addition, 
the splenic uptake was not blocked completely (12.17 
± 2.15 %ID/g, 30 µg) when comparing to non-blocked 
mice (147.9 ± 8.1 %ID/g). Thus, a good balance 
between blocking the antigen sink without displacing 
tumor uptake was achieved.  
A similar uptake in spleen and lymph nodes was 
previously shown by Tavaré et al., who developed 
CD8a-targeting antibody-based PET probes of similar 
size, such as the 64Cu-NOTA-Mbs (~80 kD) [35]. 
Compared to 64Cu-NOTA-Mbs, 89Zr-DFO-CD8a 
exhibited higher kidney accumulation (~4-6 vs. 16 ± 
3.9 %ID/g, 4 hours p.i.). This can be explained by the 
higher protein dose injected (4-12 µg 64Cu-NOTA-Mbs 
vs. 30 µg 89Zr-DFO-CD8a), which can lead to a higher 
aggregation state since high antibody concentrations 
can promote protein association and thus kidney 
trapping [36–38]. Furthermore the longer circulation 
time of 89Zr-DFO-CD8a compared to 64Cu-NOTA-Mbs 
(11.3 ± 0.09 vs. ~1 %ID/g, 4 hours p.i.) probably 
contributes to the kidney uptake due to the highly 
perfused nature of this organ. Lastly, the low pH 
environments that may exist in the kidneys and 
Kupffer cell lysosomes have been suggested to 
contribute to transchelation of 89Zr at these sites [39].  
The target-specificity was further examined by 
depletion studies, where the lowered number of 
CD8a+ cells in tumors and spleens of CD8a+ depleted 
mice as confirmed by flow cytometry, was detected by 
89Zr-DFO-CD8a PET. However, CD8a+ depleted mice 
accumulated some degree of tracer in tumors despite 
normalizing to the blood pool. Reasons for this could 
be multi-fold. PET imaging was not conducted in the 
same mice as used for flow cytometry and even 
though all mice were treated equally with CD8a+ 
depleting antibody depletion might have been 
insufficient in some mice. Another causative factor 
could be the enhanced permeability and retention 
(EPR) effect contributing to non-specific uptake of 
larger proteins such as antibodies and fragments 
hereof in tumors [40]. The tumor-to-blood ratio of 
89Zr-DFO-IgG2b was ~ 2 and represents the 
non-specific uptake of 89Zr-DFO-CD8a. Adding to 
this, an inflamed tumor microenvironment created by 
high therapeutic doses of immune-perturbing 
antibody could also contribute to a further increased 
permeability and retention of 89Zr-DFO-CD8a in 
tumors [41,42]. 
CD8a+ is mainly expressed on effector T cells but 
can also be found on regulatory T cells, natural killer 
cells and dendritic cells [43,44], all of which can be 
found at an early disease state in the tumor 
microenvironment [45,46]. This is also in line with 
previous studies suggesting that agents targeting 
immune populations might have pleiotropic effects 
on T cell dynamics as well as inducing immune cell 
trafficking into tumors [47]. It is crucial to the 
development of new imaging agents that they are 
biologically inert, especially when targeting immune 
cells. Importantly, we confirmed that our F(ab)’2 
based agents lacking the Fc domain do not deplete 
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CD8a+ cells in vivo and thus do not display any 
Fc-dependent biological activity, as expected.  
The ability of 89Zr-DFO-CD8a to detect changes 
in response to radiation therapy was not limited to 
tumoral CD8a+ cell infiltration, but whole-body 
effects such as increased splenic infiltration were also 
detected, which was confirmed by flow cytometric 
analysis. These results underline the additive value of 
whole-body visualization with PET imaging, when 
monitoring dynamic populations such as trafficking T 
lymphocytes.  
 Unlike spontaneous-derived tumors in humans, 
syngeneic tumors are often engrafted subcutaneously 
in a microenvironment that is distinct from the site of 
origin and progress more rapidly than most 
spontaneous human tumors. Despite these differences 
from human cancer, each syngeneic tumor model is 
likely to be more or less immunogenic and have a 
unique immunophenotype that may reflect tumor 
profiles in humans. Indeed, studies of the immune 
infiltrate in subcutaneous versus orthotopic tumors in 
mice have shown differences in numbers, subtypes 
and the distribution of immune cell populations, 
suggesting that the efficacy of tumor-immune 
modulating agents might be different between 
inoculation sites [48]. The level of CD4+ and CD8+ 
infiltration however, has been shown to be similar 
between subcutaneous and orthotopic colon or renal 
cancer models [49,50]. Nevertheless, orthotopic 
tumors are generally considered to be more 
immuno-suppressive in nature and less sensitive to 
immunotherapy than their subcutaneous 
counterparts [48]. Here we assessed the T cell 
infiltrate in multiple syngeneic mouse models 
representing various types of solid cancers of colon, 
breast, kidney and skin – tumor types among which 
PD-1/PD-L1 blockade has shown clinical success [51–
53]. Syngeneic tumor models were initially 
characterized by common ex vivo methods, IHC and 
flow cytometry of tumors, and classified into “hot” 
and “cold” tumors. The hot and highly immunogenic 
tumor models (Sa1N, CT26, MC38 and 4T1) were 
responsive to Sym021 treatment. The cold and poorly 
immunogenic tumor models B16F10 and P815 did not 
respond to Sym021 treatment. This response to 
immune checkpoint therapy as well as relative CD4+ 
and CD8a+ tumor numbers in syngeneic tumor 
models were similar to reported elsewhere [54–57]. 
When merely looking at the PET tumor uptake of 
89Zr-DFO-CD4 and 89Zr-DFO-CD8a across syngeneic 
mouse models, imaging of CD4+ and CD8a+ cells did 
not completely match the assessment of immune 
status by IHC and flow cytometry in this study with 
discrepancies mainly found among the immunogenic 
CT26 and MC38 models (low uptake) and poorly 
immunogenic P815 (high uptake) model. However, 
when correcting for background levels of tracer, we 
found a good agreement between the mean and 
maximum tumor-to-heart ratios and flow cytometric 
analysis of CD4+ and CD8a+, which makes sense from 
a physiological perspective when assessing different 
tumor types. Several factors besides target abundance 
are known to influence tumor accumulation of 
compounds and larger molecules, such as 
micro-vessel density, vascular permeability, stromal 
content, intra-tumoral pressure and diffusion. 
Different tumor types display a great deal of 
heterogeneity. Moreover, a large degree of 
heterogeneity is also found within tumors of the same 
type. Indeed, tumor growth responses to anti-PD-1 
antibody Sym021 therapy were rather heterogeneous 
across models and within models consistent with the 
variable therapeutic responses to monotherapy with 
PD-1 inhibitors seen among patients [58]. For these 
reasons, all concurrent analyses of the utility of 
89Zr-DFO-CD4/89Zr-DFO-CD8a PET as predictors of 
immunotherapeutic response were based on the 
background corrected tumor-to-heart values.  
We utilize here a diverse panel of syngeneic 
tumors to represent the heterogeneity found within 
patient tumors with respect to differences in 
vascularization, contributions to the EPR effect and 
response to PD-1 checkpoint inhibition, and found 
that maximum tumor-to-heart values of 89Zr-DFO- 
CD8a and to a larger degree 89Zr-DFO-CD4 were 
indicators of response to therapy. Interestingly, no 
association between the mean tumor-to-heart ratios of 
89Zr-DFO-CD4 or 89Zr-DFO-CD8a and tumor growth 
response to therapy was found. Maximum values of 
tumor imaging markers are the preferred choice 
clinically and have become the de facto standard [59]. 
Additionally, they largely relate more strongly to 
prognosis as they reflect the most aggressive 
phenotype of the tumor [60,61]. Moreover, in the 
context of immune cell markers maximum values 
might be even more applicable as immune cells are 
more dynamic, migrate and cluster at inflamed sites. 
In addition, it was demonstrated that when individual 
tumors were divided into groups with a maximum 
tumor-to-heart ratio above or below 9, 89Zr-DFO-CD4 
stratified the population into responders and 
non-responders to Sym021 therapy. Yet, the fraction 
of responders was limited to 5 out of 35 treated mice 
distributed among 3 models and the predictivity of 
89Zr-DFO-CD4 PET thus might be limited to certain 
tumor types. 
 To the best of our knowledge this is the first 
report on the predictive value of CD4+ PET imaging in 
oncology mouse models. A 89Zr-labeled CD4+ cDb has 
been evaluated in naïve [23] and colitis [62] mice as 
Theranostics 2019, Vol. 9, Issue 26 
 
 
http://www.thno.org 
8235 
well as a model of hematopoietic stem cell 
transplantation [63]. Probes targeting CTLA-4 [20,64], 
which is generally expressed on activated T cells, and 
CD3+ [22], a global T cell marker, have shown success 
in discriminating responders from non-responders 
after immunotherapy was initiated. In contrast, 
attention in other previous studies has focused on the 
cytotoxic CD8+ T cells. In these studies it was also 
indicated that immuno-PET strategies were successful 
with correlating post-therapy CD8+ PET imaging and 
response to immunotherapy in a few animal models 
[24,25,65]. Also, the CD8+-targeting minibody 
89Zr-IAB22M2C is currently being tested clinically in 
patients undergoing immunotherapy [66]. The 
radiotracers developed in our study are targeting 
murine CD4+ and CD8a+ cells. Accordingly, our 
probes can be used in preclinical studies using 
syngeneic tumor models enabling investigation of 
immunotherapy drugs in a host with a fully 
functional immune system. Currently, the majority of 
preclinical work within immuno-oncology 
development is indeed undertaken in such syngeneic 
tumor models and therefore we believe our probes are 
important additions to the available armamentarium 
within this research field. Further, to our knowledge 
no probes specific for CD4+ are presently being 
evaluated for immunotherapy assessment in the 
clinic. Indeed, the role of CD4+ T cells in the tumor 
microenvironment is of growing interest as these cells 
have been shown to be required for efficacious 
anti-tumor immunity and can target tumor cells in 
various ways (reviewed by Borst et. al. [8]). However, 
the presence of several different subtypes of CD4+ T 
cells with opposing actions on anti-tumor activity in 
the tumor microenvironment has confounded the 
efforts to specifically induce CD4+ T cell responses for 
cancer immunotherapy. Tumor-specific CD4+ T cells 
in the tumor microenvironment can be 
reprogrammed into regulatory CD4+ T cells (Tregs) that 
counteract cytotoxic T cell activity and are generally 
considered to contribute to an immuno-suppressive 
tumor microenvironment. The proportion of CD4+ 
Tregs to total CD4+ in the tumor microenvironment of 
syngeneic tumors however, has been reported to ~ 
0.5-8% [54,56]. Further, it should be noted that CD4+ 
Treg infiltration and accumulation can correlate with a 
positive prognosis in certain malignancies, including 
colorectal, gastric and NSCLC cancer [67–69]. Also, 
preclinical and clinical studies have shown that CD4+ 
T cells can induce durable immune-mediated tumor 
control, and in some cases to an even larger extent 
than CD8+ T cells [7,70–72]. Together, these findings 
place CD4+ T cells as a highly relevant actor in tumor 
immunity and thus a potential, central prognostic 
marker for outcome of cancer immunotherapy. As 
opposed to the sole purpose of CD8+ T cells at the 
tumor site, the multifaceted and wide-ranging role of 
CD4+ T cells potentially makes CD4+ a better target for 
following T cell activity by PET imaging. By 
exploiting humane antibodies, the F(ab)’2 imaging 
approach described here can easily be modified into 
clinical use warranting the further development of a 
human version of 89Zr-DFO-CD4.  
The immune frame-work in and around tumors 
is complex, making it difficult to identify broad 
biomarkers embracing a wide range of patients. The 
presence of many additional immune subsets, such as 
myeloid-derived suppressor cells and tumor- 
associated macrophages, in the periphery and the 
tumor microenvironment has been suggested to be a 
key denominator for the outcome of immunotherapy 
[73]. Imaging markers directly reflecting the 
functional status, i.e. activation or exhaustion state of 
specific cells, have the potential to be more predictive 
[74] and PET imaging of activated T cells has 
successfully been pursued [75,76] in addition to the 
secreted activation markers Granzyme B [77] and 
IFNγ [78]. Indeed, it can be debated whether a specific 
cellular subtype and/or activation state or the simple 
presence of immune cells in the tumor 
microenvironment is the paramount biomarker of 
immunotherapeutic response. Nevertheless, the PET 
signal from low abundance cell populations might not 
be sensitive enough to detect changes in response and 
imaging of CD4+ or CD8a+ TILs might be a useful 
surrogate. Future studies with a radioisotope with a 
shorter half-life, such as 64Cu (t1/2=12.7 hours) will 
enable multiple scans during and after treatment and 
ease the interpretation of data since the baseline T cell 
infiltration can vary widely, as demonstrated in this 
study.  
Conclusions 
In the present study, we developed and 
validated the specificity of PET imaging radiotracers 
for whole-body detection and assessment of CD4+ and 
CD8a+ status in preclinical mouse models. These 
radiotracers are promising candidates as powerful, 
non-invasive predictors of response during the course 
of therapy, as they can be used to phenotype tumors 
at an early stage and yet allow following the 
treatment response within the same animal at 
multiple timepoints. To the best of our knowledge, 
this is the first report demonstrating predictivity of 
tumor growth response and survival using a 
CD4+-targeting PET tracer. Furthermore, it is the first 
study linking individual baseline CD4+ or CD8a+ 
levels as visualized by PET to overall response to 
immune checkpoint inhibition. The murine F(ab)’2 
imaging approach described here can easily be 
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modified into clinical use with human antibodies and 
the potential extends beyond oncology with probable 
value in any CD4+ or CD8a+ driven indication. 
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